ArticleMedComm2026
Integrated Multi-Time-Point
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06608537 (A Single-center, Single-arm Phase II Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-center, Single-arm Phase II Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Predicting pathological complete response (pCR) after neoadjuvant short-course radiotherapy combined with immunotherapy and chemotherapy remains challenging in microsatellite-stable (MSS) locally advanced rectal cancer. In this prospective exploratory study (ClinicalTrials.gov identifier: NCT06608537), 49 patients received short-course radiotherapy followed by sintilimab plus CAPOX and subsequently underwent radical surgery. We investigated whether treatment response could be better characterized by integrating two complementary biological dimensions: baseline immune organization and treatment-related stromal remodeling captured by multi-time-point
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.